logo-loader
HealthPharma & Biotech
Dynavax Technologies

Dynavax announces layoffs, floats selloff of immuno-oncology arm

The biopharmaceutical company is cutting 82 positions, roughly 37% of its workforce

placeholder
As part of the transition, CEO Eddie Gray announced he would step down

Dynavax Technologies Corporation (NASDAQ:DVAX) shares stumbled Friday after the company announced layoffs and teased plans to sell off its immuno-oncology portfolio late Thursday.

The biopharmaceutical company is cutting 82 positions, roughly 37% of its workforce. The move, coupled with the decision to explore strategic alternatives for its immuno-oncology portfolio, is an effort to prioritize the company’s approved Hepatitis B vaccine, its first commercial product. ‘

Its stock climbed more than 8% early in the Friday session but swiftly reversed course, dropping 7.6% to $5.86.

“Following a comprehensive analysis of our assets, strengths and opportunities, we have determined we should focus our resources on our approved vaccine, HEPLISAV-B,” CEO Eddie Gray said. “As a result, the board and management have made the difficult decision to reduce our workforce. We want to express our deepest appreciation to our employees for their invaluable contributions.”

As part of the transition, Gray announced he would step down. The company named David Noack and Ryan Spencer as interim co-presidents as the company searches for a new CEO. Novack and Spencer serve as vice presidents of operations and commercial, respectively.

Dynavex is a company focused on using the body’s innate immune responses to develop vaccines. It launched HEPLISAV-B in February 2018 after receiving approval from the US Food and Drug Administration.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Dynavax Technologies

Price: $4.32

Market: NASDAQ
Market Cap: $281.47 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'May only be a matter of time' before Uranium price recovery with...

Mining Capital's Alastair Ford discusses the planned slow down in production from Kazatomprom (LON:KAP). The miner's looking to cut output from its Kazakh mines by around 20% through to 2021. He says that extends the timeframe of its previous production curtailment by a further year, and...

2 days, 4 hours ago

2 min read